Baudax Bio, Inc. (BXRXQ)
- Previous Close
0.0100 - Open
0.0068 - Bid --
- Ask --
- Day's Range
0.0068 - 0.0103 - 52 Week Range
0.0060 - 0.0240 - Volume
9,536 - Avg. Volume
102,356 - Market Cap (intraday)
449,008 - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
www.baudaxbio.comRecent News: BXRXQ
Compare To: BXRXQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BXRXQ
Valuation Measures
Market Cap
435.93k
Enterprise Value
8.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.03
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-114.93%
Return on Equity (ttm)
--
Revenue (ttm)
1.27M
Net Income Avi to Common (ttm)
-59.2M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
363k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.93M
Research Analysis: BXRXQ
Company Insights: BXRXQ
BXRXQ does not have Company Insights